Zydus Lifesciences’ venture capital arm invests in Feldan Therapeutics

17 Apr 2025 Evaluate

Zydus Lifesciences’ venture capital arm--Zynext Ventures USA LLC (Zynext Ventures) has invested in Feldan Therapeutics (Feldan), a Canada-based early clinical-stage pharmaceutical company pioneering the development of treatments based on intracellular delivery of therapeutics. 

Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities. The company's lead candidate, FLD-103, is administered directly into basal cell carcinoma (BCC) lesions, where the Shuttle peptide facilitates the delivery of a Hedgehog inhibitor to its target within BCC cells. This innovative approach aims to provide BCC patients with a non-surgical treatment option that improves outcomes and significantly enhances their quality of life. Additionally, Feldan is advancing a pulmonary program that leverages the Shuttle's unique ability to transport biomolecules into hard-to-deliver lung cells to address the unmet and growing medical needs of patients with respiratory diseases. 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


Zydus Lifesciences Share Price

922.45 -1.25 (-0.14%)
11-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.90
Dr. Reddys Lab 1272.95
Cipla 1512.10
Zydus Lifesciences 922.45
Lupin 2080.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×